June 8, 2020 10:24 AM EDT

Biopharma IPO boom yields buoyant biotech public debuts

Natalie Grover

Reporter

The past week has seen a smorgasbord of bigger-than-expected biopharma IPO debuts led by Chinese biotech Legend, as investors put their chips on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

view job offer post your job now

TRENDING NOW

Biopharma IPO boom yields buoyant biotech public debuts

Natalie Grover

Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Advocacy groups and experts call for decade-long ban on germline editing

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

CRISPR patent spat revived by federal appeals court ruling

Some generics, biosimilar drugmakers say they can withstand tariff impact

Bio­phar­ma IPO boom yields buoy­ant biotech pub­lic de­buts

Reporter

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Biopharma IPO boom yields buoyant biotech public debuts